Pacific Biosciences of California (PACB) reported $160M in revenue for fiscal 2025, +3.9% year on year. That ranks #2757 by revenue among 2853 SEC filers and #536 in Technology. It posted a net loss of −$546M for the same year. Revenue has grown 11.7% a year on average since 2011 ($33.9M then). The fiscal 2025 balance sheet shows $784M in total assets, $63.7M in cash and $897M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerIncludingAssessedTax | $160M | +3.9% | FY20252025-12-31 |
| Gross profitGrossProfit | $45.8M | +22.8% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | −$554M | −$79.5M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$546M | −$237M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$111M | +$94.8M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $2.7M | −56.1% | FY20252025-12-31 |
| Total assetsAssets | $784M | −37.8% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $5.3M | −98.9% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $63.7M | +15.1% | FY20252025-12-31 |
| Long-term debtLongTermDebt | $897M | +0.1% | FY20222022-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $37.2M | −$8.3M | Open → |
| Q2 20262026-06-30 | $39.0M | −$44.7M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Pacific Biosciences of California, Inc.
- Ticker
- PACB
- Exchange
- Nasdaq
- SIC classification
- Laboratory Analytical Instruments (3826)
- Fiscal year end
- 12-31
- CIK
- 0001299130
Filings
- 10-QAug 6, 2026Open filing →
- 10-QMay 8, 2026Open filing →
- 10-KFeb 25, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Cheetah MobileCMCM | $165M | −$36.9M |
| CLPSCLPS | $164M | −$7.0M |
| LZ TechnologyLZMH | $161M | −$24.8M |
| Pacific Biosciences of CaliforniaPACB | $160M | −$546M |
| Cambium NetworksCMBMF | $160M | −$38.5M |
| CS DiscoLAW | $157M | −$44.4M |
| StemSTEM | $156M | $138M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Pacific Biosciences of California — Key figures |url=https://companiesranked.com/en/company/pacific-biosciences-of-california |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Pacific Biosciences of California — Key figures. CompaniesRanked. https://companiesranked.com/en/company/pacific-biosciences-of-californiaBibTeX
@misc{companiesranked-en-company-pacific-biosciences-of-california-2026,
author = {{CompaniesRanked}},
title = {{Pacific Biosciences of California — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/pacific-biosciences-of-california}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001299130-26-000034 · February 25, 2026
{{cite web |title=Pacific Biosciences of California — Key figures — 10-K (0001299130-26-000034) |url=https://www.sec.gov/Archives/edgar/data/1299130/000129913026000034/pacb-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-25}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.